BIOGEN INC. (BIIB) FY2025 Annual P&L / Income Statement

BIOGEN INC. (BIIB) FY2025 Annual P&L / Income Statement

Income statement for 2025-01-01 through 2025-12-31. View: Product and service (19 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues

9,890,600,000 US dollars

Cost of sales, excluding amortization and impairment of acquired intangible assets

2,404,200,000 US dollars

Gross profit (calculated)

7,486,400,000 US dollars

Operating expenses (calculated)

5,929,900,000 US dollars

Operating profit (calculated)

1,556,500,000 US dollars

Other income (expense), net (calculated)

0 US dollars

Income before income tax (benefit) expense

1,556,500,000 US dollars

Income tax (benefit) expense

263,600,000 US dollars

Net income

1,292,900,000 US dollars

BENEPALI

453,200,000 US dollars

IMRALDI

190,200,000 US dollars

FLIXABI

52,600,000 US dollars

BYOOVIZ

32,400,000 US dollars

TOFIDENCE

700,000 US dollars

TECFIDERA

679,700,000 US dollars

VUMERITY

746,800,000 US dollars

AVONEX

695,500,000 US dollars

PLEGRIDY

250,100,000 US dollars

TYSABRI product

1,665,400,000 US dollars

FAMPYRA

1,400,000 US dollars

ZURZUVAE

195,100,000 US dollars

FUMADERM And ADUHELM

2,100,000 US dollars

SPINRAZA

1,546,800,000 US dollars

SKYCLARYS

520,500,000 US dollars

QALSODY

86,900,000 US dollars

Alzheimer's collaboration revenue

177,700,000 US dollars

Contract manufacturing, royalty and other revenue

732,900,000 US dollars

Revenue from anti-CD20 therapeutic programs

1,860,600,000 US dollars

Research and development

1,778,600,000 US dollars

Selling, general and administrative

2,433,600,000 US dollars

Amortization and impairment of acquired intangible assets

515,000,000 US dollars

Gain on sale of priority review voucher, net

0 US dollars

Collaboration profit sharing/(loss reimbursement)

290,200,000 US dollars

Other (income) expense, net

305,600,000 US dollars

(Gain) loss on fair value remeasurement of contingent consideration

33,600,000 US dollars

Restructuring charges

48,600,000 US dollars

Acquired in-process research and development, upfront and milestone expense

471,800,000 US dollars

Impairment of ROU asset

52,900,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.